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Abstract
Introduction: In patients with diabetic foot syndrome (DFS), an inadequate angiogenic response is observed. The aim of this study was to 
evaluate the concentrations of VEGF-A, PDGF-BB, sVEGF-R2 and sVEGF-R1 in patients with diabetes-complicated diabetic foot syndrome 
and analyse them using selected clinical data.
Material and methods: Forty seven diabetic patients, 25 women mean age 63 and 20 men mean age 60.5, with diabetic foot syndrome 
(DFS) were enrolled in the experimental group. To evaluate angiogenesis factors depending on Wagner grade, the subjects were divided 
into three subgroups: I — patients with 0 Wagner grade (n = 14); II — patients with 1,2,3 Wagner grades (n = 15); and III — patients with 
4,5 Wagner grades (n = 18). The control group consisted of 20 healthy volunteers. The material for research was blood. 
Results: Significantly higher levels of VEGF-A and PDGF-BB in the DFS cases compared to controls were observed (VEGF-A p = 0.000001; 
PDGF-BB p = 0.000051). Analysis of angiogenic parameters according to the stage of diabetic foot syndrome advancement showed higher 
VEGF-A level (I: p = 0.000867; II: p = 0.001827; III: p = 0.000024) and PDGF-BB (respectively p = 0.004113, p = 0.004224, p = 0.002480) in 
all the subgroups. Decreased sVEGF-R2 concentrations were observed in the I (p = 0.054) subgroup and the III (p = 0.03524) subgroup. 
In this study, a strong positive correlation between VEGF-A and PDGF-BB was observed (R = 0.66; p = 0.000001). 
Conclusions: Our study revealed that proangiogenic factor levels were increased in DFS. This is associated with lower limb ischae-
mia and hypoxic conditions. The stage of diabetic foot syndrome advancement influenced VEGF-A and PDGF-BB concentrations. 
(Endokrynol Pol 2014; 65 (4):306–312)
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Streszczenie
Wstęp: U pacjentów z zespołem stopy cukrzycowej (DFS) obserwuje się nieprawidłową odpowiedź angiogenną. Celem naszej pracy 
była ocena stężenia VEGF-A,PDGF-BB, sVEGF-R2 i sVEGF-R1u pacjentów z cukrzycą powikłaną ZSC oraz ich analiza pod względem 
wybranych parametrów klinicznych.
Materiał i metody: Do badania zakwalifikowano 47 pacjentów z ZSC: 25 kobiet (średnia wieku 63 lata), 22 mężczyzn (średnia wieku 
60,5 lata). Aby uwzględnić stopień zaawansowania zmian, grupa badana została podzielona na 3 podgrupy: I — 0 stopień Wagnera 
(n = 14), II — 1, 2, 3 stopień Wagnera (n = 15) oraz III — 4, 5 stopień Wagnera (n = 18). Grupę kontrolną stanowiło 20 zdrowych ochot-
ników. Materiałem do badań była krew żylna.
Wyniki: Zaobserwowano znacząco wyższe stężenia VEGF-A I PDGF-BB u pacjentów w porównaniu do grupy kontrolnej (VEGF-A 
p = 0,000001; PDGF-BB p = 0,000051). Analizując badane parametry z uwzględnieniem stopnia zaawansowania zmian odnotowano 
wysokie stężenia VEGF-A (I: p = 0,000867; II: p = 0,001827; III: p = 0,000024) i PDGF-BB (odpowiednio p = 0,004113, p = 0,004224, 
p = 0,002480) we wszystkich podgrupach. Obniżone stężenie sVEGF-R2 zaobserwowano w I (p = 0,054) i w III (p = 0,03524) podgrupie. 
W badaniu wykazano pozytywną zależność między stężeniem VEGF-A I PDGF-BB (R = 0,66; p = 0,000001). 
Wnioski: U pacjentów zaobserwowano podwyższone stężenia czynników proangiogennych, co związane jest z silnym niedokrwieniem 
kończyny dolnej oraz istniejącym stanem hipoksji. Stopień zaawansowania zmian znacząco wpływa na stężenia VEGF-A i PDGF-BB. 
(Endokrynol Pol 2014; 65 (4): 306–312)
Słowa kluczowe: angiogeneza; zespół stopy cukrzycowej; naczyniowo śródbłonkowy czynnik wzrostu; płytkopochodny czynnik wzrostu
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The complexity of angiogenesis, the variety of growth 
factors and cytokines taking part in this process, the 
function of the endothelial progenitor cells, and an 
increasing role for this process in the pathogenesis of 
many diseases has meant that angiogenesis has been 
arousing increasing interest in the world of science. 
In this remarkable process of blood vessel formation, 
a lot of cytokines and growth factors are involved, of 
which vascular endothelial growth factors are the most 
important. 
Angiogenesis plays an important role in wound heal-
ing. Healing begins at the moment of tissue injury, and 
the whole process can take weeks, months or even years. 
The process of wound healing includes four stages: 
haemostasis, inflammation, proliferation and tissue 
remodelling [1, 2]. Vasoconstriction, platelet adhesion, 
aggregation and their degranulation and the activation 
of plasma cascade coagulation occur at the site of the 
injured vessel. In the inflammatory phase, neutrophils, 
monocytes/macrophages and lymphocytes are involved. 
These cells migrate from the circulation in response to 
chemotactic factors released from injured tissue and by 
other inflammatory cells [1]. Proliferation includes epi-
thelialisation, collagen synthesis, matrix formation and 
angiogenesis [1]. The final phase of wound healing con-
sists of collagen remodelling, fibroblast transformation 
into myofibroblasts, and extracellular matrix reorganisa-
tion [1–3]. The reconstruction of vascular structures in 
damaged tissue is the most important stage of healing 
due to the restoration of normal blood circulation [3].
Physiologically, angiogenesis is a dynamic process 
regulated by numerous factors, and a strong balance 
is preserved between stimulators and inhibitors. Fully 
matured, correctly functioning blood vessel formation 
requires the co-operation of all cytokines, integrins, 
and receptor proteins because a deficiency, excess or 
malfunction of one component of the cascade process 
may contribute to pathological angiogenesis develop-
ment. Abnormal blood vessel creation and associated 
impaired wound healing are observed in patients with 
diabetic foot syndrome (DFS). 
In 2011, according to the International Diabetes 
Federation, 366 million people worldwide suffered from 
diabetes [4]. Diabetic foot syndrome is characterised by 
a triad: neuropathy, ischaemia and infection is a most 
unfortunate late diabetic complication due to reduced 
quality of life associated with amputation. Infections are 
the most frequent consequence of DFS and led to non-
healing wounds resulting from impaired angiogenesis. 
15%-20% of patients with DFS require amputation [5]. 
Improving the process of blood vessel formation is as-
sociated with the acceleration of wound healing. 
In 1997, the US Food and Drug Administration 
approved only one growth factor for the treatment of 
chronic lower extremity diabetic neuropathic ulcers, 
which was rhPDGF-BB [6]. Platelet-derived growth 
factor (PDGF) is responsible for angiogenesis induction, 
and in co-operation with basic fibroblast growth factor 
stabilises the newly formed vessels by pericytes recruit-
ment [7, 8]. Thus PDGF plays an essential role in all 
stages of blood vessel creation: in the early days of an-
giogenesis, it is released from platelets and endothelial 
cells, and after a few weeks it takes part in remodelling 
involving collagen turnover and cross-linking. PDGF 
freed from platelets acts chemotactically for neutrophils, 
macrophages and fibroblasts that migrate into the site of 
injured tissue. After 2–3 weeks, collagenase expression, 
active collagen turnover and cross-linking are the effect 
of PDGF [6]. PDGF induces vascular structure formation 
through priming vascular smooth muscle cells/peri-
cytes (VSMCs/pericytes) to release angiogenic factors, 
including vascular endothelial growth factor (VEGF) 
[6]. PDGF-AB (heterodimer) is freed by platelets, and 
PDGF-BB (homodimer) is synthesised by endothelial 
cells (ECs), megakaryocytes and muscle cells. Both het-
erodimer and homodimer initiate pericytes migration 
and proliferation, although the more effective action in 
maintaining vessel stability is shown by PDGF-BB [7]. 
VEGF also stabilises newly formed vascular tu-
bules. VEGF-A directly stimulates ECs proliferation 
and migration [9]. Hypoxia inducible factor-1 (HIF-1) 
is a transcription factor regulating VEGF expression. 
VEGF-A is produced by many cells: endothelial cells, 
smooth muscle cells, keratinocytes, and macrophages, 
and acts via its specific receptors, mainly VEGF-R1 and 
VEGF-R2 [10, 11]. 
Patients with type 2 diabetes are a special group of 
patients because of the development of late diabetic 
vascular complications. Diabetic retinopathy is char-
acterised by abnormal excessive angiogenesis with 
elevated VEGF levels. On the other hand, impaired 
wound healing is observed in patients with DFS. This 
pathological process results from impaired angiogen-
esis. There have been many studies into the role of 
PDGF in DFS treatment and VEGF in retinopathy or 
nephropathy. Unfortunately, very little information 
is available regarding VEGF-A and PDGF-BB con-
centrations and their relationship in patients with 
DFS. VEGF-A is predominantly involved in the early 
stages of angiogenesis (activating vascular structure 
formation), while the role of PDGF-BB is focused 
on the final stage of this process (stabilising already 
formed vessels). 
Therefore, the aim of this study was to evaluate 
the concentrations of VEGF-A, sVEGF-R1, sVEGF-R2 
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diabetic foot syndrome and analyse them using selected 
clinical data.
 Material and methods
Forty seven diabetic patients with diabetic foot syn-
drome were enrolled in the experimental group. 
Patients were treated in the Diabetic Foot Clinic, 
University Hospital and the Department of Vascular 
Surgery and Angiology, University Hospital of A. Ju-
rasz, in Bydgoszcz, Poland. The criteria for inclusion 
in the study were: glycated haemoglobin value above 
7.0% (mean 8.3%) providing poor diabetes control and 
the presence of vascular complication with diagnosed 
diabetic foot syndrome and classified grade of lesions 
according to the Wagner classification. Patients were 
qualified for this study on the basis of history and 
physical examination including vascular research. 
The patients were treated with insulin, appropriate 
diet and physical effort. The comparative analysis of 
the examined group included the influence of factors 
such as: body mass index (BMI), Wagner grade (Grade 
0: no ulcer in a high risk foot, Grade 1: superficial ulcer 
involving the full skin thickness but not underlying 
tissues, Grade 2: deep ulcer, penetrating down to liga-
ments and muscle, but no bone involvement or abscess 
formation, Grade 3: deep ulcer with cellulitis or abscess 
formation, often with osteomyelitis, Grade 4: localised 
gangrene, Grade 5: extensive gangrene involving the 
whole foot)[Wagner 1983], diabetes duration, and DFS 
duration on measured parameters. 
To evaluate angiogenesis factors depending on the 
Wagner grade, the subjects were divided into three 
subgroups: I — patients with 0 Wagner grade (without 
oxygen deficiency and normal wound healing; n = 14); 
II — patients with 1,2,3 Wagner grades (ischaemia, 
impaired wound healing, inflammation; n = 15); and 
III - patients with 4,5 Wagner grades (critical ischaemia, 
necrosis; n = 18). Any patient who was being treated 
with medications affecting haemostasis, or had had 
an operation within the last month, or who had end 
stage renal failure, chronic liver disease or any other 
severe medical condition requiring active treatment 
was excluded from this study. The characteristics of 
the subjects in terms of gender are set out in Table I. 
The diabetes duration and DFS duration were longer 
in women than in men. The women enrolled into this 
study were older compared to the men. However, 
the men had the most advanced lesions classified as 
Wagner grades 4 or 5. The following accompanying 
diseases were reported: arterial hypertension (n = 33), 
myocardial infarction (n = 2), ischaemic heart disease 
(n = 9), and lipid disorders (n = 17). In addition, 
11 subjects had nephropathy. 
The control group consisted of 20 healthy volunteers 
selected with regard to age and gender. This study was 
conducted according to the tenets of the Declaration of 
Helsinki. The Bioethics Commission of the Collegium 
Medicum in Bydgoszcz Nicolaus Copernicus Univer-
sity in Toruń approved the experimental protocol (no. 
KB/367/2009). All patients were informed about the 
aim of the study and they signed their agreement to 
participate. 
The material for research was blood plasma. The 
blood samples were drawn from the antecubital vein 
after 12 hours of fasting. The plasma samples were 
obtained from the whole blood collected into tubes 
containing EDTA and centrifuged at 3,000 rpm for 
15 minutes. All the samples were stored at –80°C until 
analysis, for no longer than six months. The concentra-
tions of soluble VEGF receptors were determined in 
the plasma samples. PDGF and VEGF concentrations 
were determined in the plasma samples considering 
the known release of them by platelets. The growth 
factors and receptors were measured using ELISA kit: 
Quantikine Human Immunoassay (R&D Systems, Min-
neapolis, MN, USA).
Statistical analysis
The statistical analysis was performed using Statis-
tica 8.0 for Windows (StatSoft). Shapiro-Wilk test 
was used for the evaluation of variables distribution. 
The parameters with parametrical distribution were 
analysed in the groups using Student-t test and were 
described with mean (X) and standard deviation (SD). 
U-Mann-Whitney rank-sum test was used for variables 
with non-parametrical distribution. These parameters 
were presented as median (Me), upper quartile (Q1) 
Table I. Clinical characteristics of studied subjects
Tabela I. Charakterystyka kliniczna pacjentów
Parameter Women Men
Age (mean) (years) 63 60.5
DM duration(mean) (years) 20 16.5
Type DM 1/2 1/24 1/21
DFS duration (mean) (years) 4 2
Wagner grade 0 7 7
Wagner grades 1–3 10 5
Wagner grades 4–5 8 10
Smoking 14 18
BMI (mean) [kg/m2] 28 30.7
Hypertension 19 15
Heart infarction 1 1
Ischaemic heart disease 5 4
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and lower quartile (Q3), as well as a range of values 
minimum and maximum. The comparison of a larger 
number of groups was performed by ANOVA. For 
nonparametric data, the Spearman correlation coef-
ficient was used. The analysis of correlation between 
parameters with normal distribution was done through 
Pearson correlation coefficient. A P-value of < 0.05 was 
considered statistically significant.
Results
Table II shows angiogenesis parameters in patients with 
DFS and healthy volunteers. sVEGF-R1 and sVEGF-R2 
concentrations are presented as average and standard 
deviation (parametric distribution), while VEGF-A and 
PDGF-BB concentrations are described with median 
and quartiles. Significantly higher levels of VEGF-A 
and PDGF-BB in the study group compared to the 
control group were observed. The differences were 
statistically significant (VEGF-A p = 0.000001; PDGF-BB 
p = 0.000051). There were no significant differences in 
VEGF receptors between patients and controls.
Our analysis of the angiogenesis parameters includ-
ing Wagner grades demonstrated significantly higher 
VEGF-A level in all the subgroups compared to the 
control group (I: p = 0.000867; II: p = 0.001827; III: 
p = 0.000024) (Fig. 1). The highest VEGF-A concentra-
tion was noted in the III subgroup. PDGF-BB concentra-
tion was statistically significantly higher in all the sub-
groups than in the controls (respectively p = 0.004113, 
p = 0.004224, p = 0.002480) (Fig. 2). The patients with 
grade 0 had the highest PDGF-BB concentration. Statis-
tically significant decreased sVEGF-R2 concentrations 
were observed in the I subgroup (p = 0.054) and the III 
subgroup (p = 0.03524) compared to the control group. 
No statistically significant difference was observed in 
sVEGF-R1 concentration. For further research, the an-
giogenic variables were tested among the subgroups. 
No statistically significant differences were noted while 
analysing I vs. II, I vs. III and II vs. III. Based on the 
Spearman coefficient, a strong positive correlation be-
tween VEGF-A and PDGF-BB was observed (R = 0.66; 
p = 0.000001). The positive value of coefficient correla-
tion shows the coexistence of increased concentrations 
Table II. VEGF-A, sVEGF-R1, sVEGF-R2, and PDGF-BB levels in the study group compared to the control group








X/Me SD/Q1;Q3 X/Me SD/Q1;Q3
VEGF-A 70.84 40.11;198.57 26.87 25.22;27.51 0.000001
sVEGF-R1 137.16 49.48 119.90 71.12 0.27
sVEGF-R2 9,182.32 3,742.56 10,693.13 1,716.52 0.09
PDGF-BB 375.55 198.40;868.26 118.78 49.18;209.63 0.00005
X — mean; Me — median; SD — standard deviation; Q1 — lower quartile; Q3 — upper quartile; p-value; p < 0.05 statistical significant
Figure 1. VEGF-A level in patients divided into the subgroups 
compared to the control group; Data is presented as the median; 
*p significant
Rycina 1. Stężenie VEGF-A u pacjentów w podgupach oraz 
w grupie kontrolnej
Figure 2. PDGF-BB level in patients divided into the subgroups 
compared to the control group ; Data is presented as the median; 
*p significant














VEGF-A and PDGF-BB in DFS   Ewelina Drela et al.
of VEGF-A and PDGF-BB. This relation is illustrated in 
Figure 3. Moreover, a negative correlation of sVEGF-
R2 concentration and age was observed (R = –0.33; 
p = 0.032833), as well as a negative correlation of PDGF-BB 
concentration and age (R = –0.31; p = 0.035032). 
Discussion
It is known that in patients with diabetes, the levels 
of proangiogenic factors are decreased. Our findings 
are therefore controversial. In this study, we observed 
increased VEGF-A and PDGF-BB concentrations in 
patients with diabetic foot syndrome. 
Angiogenesis plays a pivotal role in wound healing 
[10]. VEGF is the main factor inducing both physiologi-
cal and pathological angiogenesis. This specific mitogen 
for vascular endothelial cells is synthesised by the en-
dothelial cells, myocytes, macrophages, lymphocytes 
CD4+, and megakaryocytes [11, 12]. It is stored in 
leukocytes and platelets from where it is released into 
the circulation in a hypoxic condition [12] and under the 
influence of IL-6 and IL-8. Hypoxia, acting via hypoxia 
inducible factor-1a (HIF-1a) is the most important factor 
that enhances VEGF-A expression. Our data showed an 
increased VEGF-A concentration in the patients with 
DFS compared to the control group. The reasons for 
the increased VEGF-A level are complex. Patients with 
DFS are characterised by impaired perfusion leading 
to hypoxia. Hypoxia activates VEGF-A expression. 
Analysis of the study group based on Wagner clas-
sification showed that patients with Wagner grades 
4 and 5 (grade 4: localised gangrene, grade 5: extensive 
gangrene involving the whole foot) [13] had a two-
fold higher VEGF-A concentration than patients with 
Wagner grade 0 (grade 0: no ulcer in a high risk foot) 
and four-fold higher compared to the control group. 
We suggest that this may result from the deep mi-
crocirculation disturbance in the ischaemic area and 
severe tissue hypoxia. 
It is postulated that overexpression of VEGF-A 
in patients with DFS is also associated with chronic 
inflammation. The inflammatory process presents in 
patients with grade 2 and above according to the Wag-
ner classification. Increased levels of proinflammatory 
cytokines such as C-reactive protein, fibrinogen, IL-6, 
IL-1, and tumour necrosis factor a (TNF-a) have been 
observed in diabetic patients [14]. The elevated level 
of IL-6 contributes to the release of VEGF-A stored in 
platelets and leukocytes. The average value of patients’ 
BMI was 29.4, i.e. most patients were overweight or 
obese. Adipose tissue is considered to be an endocrine 
organ and releases hormones, enzymes and cytokines, 
including VEGF and IL-6 [14, 15]. In 2010, Loebig et al. 
observed a positive correlation between BMI and serum 
VEGF level [15]. A similar result was obtained by Doupis 
et al. Their research showed increased VEGF level in 
the serum of non-obese patients with diabetes, and 
in obese patients with diabetes. However, the highest 
concentration of VEGF was observed in the group of 
obese non-diabetics [16].
Unfortunately, there is not enough data in the avail-
able literature about VEGF-A concentration in diabetic 
patients complicated by DFS. The concentration of vas-
cular endothelial growth factor varies greatly in other 
late complications of diabetes such as nephropathy 
and retinopathy. In patients with proliferative diabetic 
retinopathy, an increased level of VEGF-A in the vitrous 
and aqueous body of the eye was noted [17]. The stud-
ies conducted by Izuta et al. also showed an elevated 
level of VEGF-A in the vitrous body [18]. In diabetic 
nephropathy, VEGF-A expression is dependent on the 
severity of changes in the glomeruli. At the early stages 
of diabetic nephropathy, an increasing expression of 
VEGF-A is observed, then the expression decreases 
[19, 20]. Moreover, in patients with type 2 diabetes, the 
urine VEGF-A concentration is elevated [21]. In our 
study, the influence of other microvascular complica-
tions (retinopathy, nephropathy) on concentrations of 
VEGF and PDGF in patients with DFS was investigated. 
There were no statistically significant differences in 
concentrations of angiogenic parameters in patients 
with and without retinopathy and in patients with and 
without nephropathy. 
On the other hand, VEGF-A levels may be due to 
differences in the genotype of VEGF in diabetic patients. 
The research conducted by Bleda et al. shows that VEGF 
gene polymorphisms predispose to different vascular 
complications of diabetes. What is more, the –2578 CA 
Figure 3. The correlation between VEGF-A and PDGF-BB 
concentrations
Rycina 3. Zależność pomiędzy stężeniem VEGF-A i PDGF-BB
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genotype was associated with a statistically significant 
increase in the concentration of VEGF in serum [Bleda 
2011].
The haemostasis process is abnormal in patients 
with diabetes.  The study conducted by Roth et. al. 
indicated a reduced mitogenic activity of VEGF-A165 as 
a result of plasmin cutting (VEGF-A165 faster degrada-
tion in non-healing ulcers) [23]. This may suggest that 
the action of VEGF is not effective due to its premature 
inactivation.
Vascular maturation is the final stage of angiogen-
esis. This process involves pericytes that cover newly 
formed vessels and it is controlled by PDGF [24]. We 
observed an elevated level of PDGF-BB in patients with 
DFS compared to healthy subjects. The analysis of the 
study group divided into subgroups according to their 
Wagner grade was particularly interesting. The highest 
concentration of PDGF-BB was observed in subgroup 
I (Wagner 0). This result shows that the concentration 
of PDGF-BB was decreasing with the progress of the 
changes. We suggest that this may be associated with 
progressive endothelium damage. Endothelial cells 
do not function properly, therefore they are not able 
to synthesise and release PDGF-BB. Armulik et al. 
showed that the knockout of PDGF and PDGFR leads to 
abnormalities in the structure of blood vessels. The lack 
of pericytes has secondary effects on endothelial cells 
contributing to endothelium hyperplasia, cell connec-
tion disorders, and excessive liminal membrane folds. 
The endothelial dysfunction is compensated for by the 
increasing VEGF-A secretion [25]. On the other hand, 
the advance of hypoxia induces HIF-1a, which activates 
the PDGF gene. Therefore, in spite of the decreasing 
concentration of PDGF-BB in the subgroups, it is still 
higher compared to the control group.
The data about PDGF presented in the literature is 
inconclusive. In 2009, Doupis et al. published a study 
which showed that PDGF-AA concentration was 
reduced in patients with painful, and painless, neu-
ropathy compared to a control group. However, the 
concentration of PDGF in the combination AB/BB was 
elevated in both study groups [26]. Three years later, 
Doupis et al. presented decreased levels of PDGF-AA in 
the serum of non-obese diabetic patients and obese dia-
betic patients [16]. Animal studies conducted by Tanii et 
al. demonstrated that in STZ-DM mice (streptozotocin 
induced diabetes mellitus), PDGF-B gene expression 
is impaired. The accumulation of AGEs (advanced 
glycation end products) was associated with reduced 
PDGF-B expression. The supplementation of PDGF-B 
gene restored normal level of PDGF-BB in the tissue and 
protected against ischaemic limb autoamputation [27].
The results of our study indicate a decreased level 
of sVEGF-R2 in patients with DFS in the subgroup with 
Wagner grades 4–5. This may reflect the wearing out 
of the receptor and deficiency in its expression by the 
damaged endothelial cells. In the available literature, 
we did not find any information about sVEGF-R2 con-
centrations in patients with DFS.
The presented results demonstrate a relationship 
between a high level of VEGF-A and a high level 
of PDGF-BB. This might prove intensified hypoxia, 
which regulates the expression of both genes [28–30]. 
Furthermore, the study conducted by Ball et al. on 
a cellular model indicated that VEGF-A acts through 
PDGF receptors (PDGF-Ra and PDGF-Rb). Further-
more, VEGF-A165 competes with PDGF-AA and-BB for 
binding to mesenchymal stem cells [31]. 
The results of our study show elevated levels of 
angiogenic factors in patients with DFS. Nevertheless, 
angiogenesis and the associated wound healing are 
impaired. In patients with diabetes, especially compli-
cated by diabetic foot syndrome, ischaemic changes are 
so strong that they contribute to VEGF-A overexpres-
sion. Greenberg et al. noted that VEGF might act as an 
antiangiogenic factor. The authors postulate that con-
necting VEGF-A with VEGF-R2 inhibits the binding of 
PDGF to PDGF-Rb. Consequently, it leads to unstable 
blood vessel creation [9]. In our study, we assessed the 
concentration of the soluble forms of VEGF receptors, 
which are classified as angiogenesis inhibitors [29]. 
Although VEGF in patients with DFS is present in the 
circulation in large amounts, it seems that its angiogenic 
activity is abolished by the formation of the complex 
with sVEGF-R2.
We found a positive correlation between VEGF-A 
and PDGF-BB (in the whole study group, without divid-
ing into subgroups). This might be associated with the 
regulation of the expression of one factor by another. 
Hypoxic VEGF transcriptional activity is controlled by 
a number of cytokines and factors, including by PDGF 
[29]. 
Determining the concentration of VEGF-A in pa-
tients with DFS may be useful in selecting appropriate 
therapy. The research carried out by Skóra et al. shows 
that administration of VEGF gene with simultaneous 
autotransplantation mononuclear bone marrow cells 
leads to elevated levels of VEGF. They noted that this 
therapy improved critical limb ischaemia [32].
Conclusions
Our study has demonstrated increased VEGF-A and 
PDGF-BB concentrations in diabetic patients with 
DFS. This is associated with lower limb ischaemia and 
hypoxic conditions. The highly significant positive cor-
relation between VEGF-A and PDGF-BB shows their 
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angiogenesis and wound healing on a limb complicated 
by DFS indicates the ineffectiveness of these factors, 
something that may result from sVEGF-R2 inhibition.
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